UNLIMITED TURBO LONG - IPSEN | Market Closed - Euronext Paris 12:30:01 2024-05-30 EDT | ||
| 1.195 EUR | +1.70% |
|
| Current month | +32.04% | ||
| 1 month | +32.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IPSEN
| Date | Price | Change |
|---|---|---|
| 24-05-30 | 1.195 | +1.70% |
| 24-05-29 | 1.175 | +2.62% |
| 24-05-28 | 1.145 | -8.40% |
| 24-05-27 | 1.25 | -7.41% |
| 24-05-24 | 1.35 | -1.46% |
Real-time Euronext Paris
Last update May 30, 2024 at 12:30 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | IPSEN |
| Issuer | 
BNP Paribas
|
| U62HB | |
| ISIN | FRBNPP04HZ83 |
| Date issued | 2022-07-07 |
| Strike | 97.12 € |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 0.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.965 € |
|---|---|
| Lowest since issue | 0.19 € |
Company Profile
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
-
Consensus: Ipsen
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
120
EUR
Average target price
126.4
EUR
Spread / Average Target
+5.33%
- Stock Market
- Certificates
- U62HB Certificat
